Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aprea Therapeutics, Inc.APRE · Entity 7948 | Director | June 16, 2026 | June 17, 2026 |
| ONCOLYTICS BIOTECH INCONCY · Entity 6721 | Director | June 01, 2026 | June 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aprea Therapeutics, Inc.
Report date June 16, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,910 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 3,135 · Balance 48,910 F1: These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.73 · Expires 2036-06-16 | Direct | 12,555 |
Reported balance
After 2026-06-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-16 · Grant · Acquired 12,555 · Balance 12,555 F2: The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
F2: The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
ONCOLYTICS BIOTECH INC
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.06 · Expires 2036-06-01 | Direct | 30,000 |
Reported balance
After 2026-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 30,000 · Balance 30,000 F1: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026. F2: The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026.
F2: The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Aptose Biosciences Inc.
Report date June 30, 2026 · Filed July 02, 2026
Section 16 reporting ended · disclosed 2026-07-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-06-30 transaction · row 1
1 source rowRow 1 · 2026-06-30 · Disposition to issuer · Disposed 17,000 · Balance 0 F1: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean Corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. F2: Converted from Canadian price of C$2.41 per share using an exchange rate of C$1.4 = US$1.00. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.00 · Expires 2034-02-05 | Direct | 0 |
Reported balance
After 2026-06-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-30 · Disposition to issuer · Disposed 3,333 · Balance 0 F1: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean Corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. F3: Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on second anniversary of the grant date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.66 · Expires 2033-01-19 | Direct | 0 |
Reported balance
After 2026-06-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-30 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean Corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. F3: Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on second anniversary of the grant date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.74 · Expires 2032-09-14 | Direct | 0 |
Reported balance
After 2026-06-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-30 · Disposition to issuer · Disposed 50,000 · Balance 0 F1: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean Corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. F3: Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on second anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean Corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share.
F2: Converted from Canadian price of C$2.41 per share using an exchange rate of C$1.4 = US$1.00.
F3: Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on second anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 2, 2026 15:01 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | Disposition to issuerStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0000912282-26-000902 · form4.xml · derivative · entry 4 Seizinger Bernd R. · CIK 0001789042 · FORMER DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 50,000 shares Expires 2032-09-14 F1 · kind: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean Corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. F3 · derivative.exercise_date: Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on second anniversary of the grant date. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 15:01 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | Disposition to issuerStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0000912282-26-000902 · form4.xml · derivative · entry 3 Seizinger Bernd R. · CIK 0001789042 · FORMER DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 100,000 shares Expires 2033-01-19 F1 · kind: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean Corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. F3 · derivative.exercise_date: Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on second anniversary of the grant date. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 15:01 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | Disposition to issuerDirector Stock Option (Right to Buy) · Derivative | 3,333 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0000912282-26-000902 · form4.xml · derivative · entry 2 Seizinger Bernd R. · CIK 0001789042 · FORMER DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 3,333 shares Expires 2034-02-05 F1 · kind: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean Corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. F3 · derivative.exercise_date: Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on second anniversary of the grant date. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 15:01 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | Disposition to issuerCommon Shares | 17,000 | $1.72 | $29,240.00 |
DisclosureSEC source: 0000912282-26-000902 · form4.xml · nonDerivative · entry 1 Seizinger Bernd R. · CIK 0001789042 · FORMER DIRECTOR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean Corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share. F2 · price: Converted from Canadian price of C$2.41 per share using an exchange rate of C$1.4 = US$1.00. Read SEC document |
| June 16, 2026 Filed Jun 17, 2026 23:02 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Options (Right to Buy) · Derivative | 12,555 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001104659-26-075278 · tm2618211-1_4seq1.xml · derivative · entry 2 Seizinger Bernd R. · CIK 0001789042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,555 Underlying: Common Stock · 12,555 shares Expires 2036-06-16 F2 · derivative.exercise_date: The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| June 16, 2026 Filed Jun 17, 2026 23:02 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 3,135 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-075278 · tm2618211-1_4seq1.xml · nonDerivative · entry 1 Seizinger Bernd R. · CIK 0001789042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,910 F1 · shares: These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 20:30 UTC | ONCOLYTICS BIOTECH INC ONCY · Entity 6721 | GrantStock Option · Derivative | 30,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001493152-26-027081 · ownership.xml · derivative · entry 1 Seizinger Bernd R. · CIK 0001789042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2036-06-01 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026. F2 · derivative.exercise_date: The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date. Read SEC document |
| February 12, 2026 Filed Feb 13, 2026 12:00 UTC | ONCOLYTICS BIOTECH INC ONCY · Entity 6721 | PurchaseCommon Shares | 40,000 | $0.85 | $33,864.00 |
DisclosureSEC source: 0001493152-26-006548 · ownership.xml · nonDerivative · entry 2 Seizinger Bernd R. · CIK 0001789042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 566,991 Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 12:00 UTC | ONCOLYTICS BIOTECH INC ONCY · Entity 6721 | PurchaseCommon Shares | 60,000 | $0.83 | $49,590.00 |
DisclosureSEC source: 0001493152-26-006548 · ownership.xml · nonDerivative · entry 1 Seizinger Bernd R. · CIK 0001789042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 526,991 Read SEC document |
| January 16, 2026 Filed Jan 20, 2026 21:30 UTC | ONCOLYTICS BIOTECH INC ONCY · Entity 6721 | PurchaseCommon Shares | 100,000 | $1.04 | $103,770.00 |
DisclosureSEC source: 0001493152-26-002879 · ownership.xml · nonDerivative · entry 1 Seizinger Bernd R. · CIK 0001789042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 466,991 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.0294 to $1.0499, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:07 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Options (Right to Buy) · Derivative | 4,185 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001104659-25-057823 · tm2517366-8_4seq1.xml · derivative · entry 2 Seizinger Bernd R. · CIK 0001789042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,185 Underlying: Common Stock · 4,185 shares Expires 2035-06-05 F2 · derivative.exercise_date: The option vests in full on June 5, 2026, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:07 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 1,045 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-057823 · tm2517366-8_4seq1.xml · nonDerivative · entry 1 Seizinger Bernd R. · CIK 0001789042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,775 F1 · shares: These shares represent restricted stock units which were granted on June 5, 2025, and which will vest and be settled in common stock on June 5, 2026, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| October 11, 2024 Filed Oct 15, 2024 12:31 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchaseCommon Stock | 10,000 | $2.68 | $26,800.00 |
DisclosureSEC source: 0001104659-24-108377 · tm2426059-4_4seq1.xml · nonDerivative · entry 1 Seizinger Bernd R. · CIK 0001789042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,730 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.52 to $2.70, inclusive. The reporting person undertakes to provide to the issuer or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 20:20 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Options (Right to Buy) · Derivative | 4,185 | $0.00 Strike: $4.07 | $0.00 |
DisclosureSEC source: 0001104659-24-073950 · tm2417666-6_4seq1.xml · derivative · entry 2 Seizinger Bernd R. · CIK 0001789042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,185 Underlying: Common Stock · 4,185 shares Expires 2034-06-20 F2 · derivative.exercise_date: The option vests in full on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 20:20 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 1,045 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-073950 · tm2417666-6_4seq1.xml · nonDerivative · entry 1 Seizinger Bernd R. · CIK 0001789042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,730 F1 · shares: These shares represent restricted stock units which were granted on June 20, 2024, and which will vest and be settled in common stock on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 00:53 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchaseTranche B Warrant · Derivative | 3,430 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-034672 · tm248935-3_4seq1.xml · derivative · entry 3 Seizinger Bernd R. · CIK 0001789042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,430 Underlying: Common Stock · 3,430 shares Expires not disclosed F4 · derivative.exercise_price: The exercise price of the Tranche B Warrants is as follows: 3,430 shares of the Company's common stock at the exercise price of $9.1125 per share or warrants for an exercise price of $9.1125 minus $0.001 per share. F6 · price: The purchase price for the Tranche B Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above. F5 · derivative.expiration_date: Tranche B Warrants shall expire on March 13, 2029; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for APR-1051, and (ii) the daily VWAP of the Common Stock equals or exceeds $18.225 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 00:53 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchaseTranche A Warrant · Derivative | 3,430 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-034672 · tm248935-3_4seq1.xml · derivative · entry 2 Seizinger Bernd R. · CIK 0001789042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,430 Underlying: Common Stock · 3,430 shares Expires not disclosed F1 · derivative.exercise_price: The exercise price of the Tranche A Warrants is as follows: 3,430 shares of the Company's common stock at the exercise price of $7.29 per share or warrants for an exercise price of $7.29 minus $0.001 per share. F3 · price: The purchase price for the Tranche A Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above. F2 · derivative.expiration_date: Tranche A Warrants shall expire on March 13, 2027; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for ATRN-119, and (ii) the daily VWAP of the Common Stock equals or exceeds $14.58 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 00:53 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchaseCommon Stock | 6,860 | $7.29 | $50,009.40 |
DisclosureSEC source: 0001104659-24-034672 · tm248935-3_4seq1.xml · nonDerivative · entry 1 Seizinger Bernd R. · CIK 0001789042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,685 Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 21:56 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | GrantDirector Stock Option (Right to Buy) · Derivative | 3,333 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0000912282-24-000126 · form4.xml · derivative · entry 1 Seizinger Bernd R. · CIK 0001789042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,333 Underlying: Common Shares · 3,333 shares Expires 2034-02-05 F1 · derivative.exercise_date: The options vest as follows: 50% on February 5, 2025; 25% on February 5, 2026; and 25% on February 5, 2027. Read SEC document |
| September 22, 2023 Filed Sep 25, 2023 21:03 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | PurchaseCommon Shares | 17,000 | $3.14 | $53,380.00 |
DisclosureSEC source: 0000912282-23-000385 · form4.xml · nonDerivative · entry 1 Seizinger Bernd R. · CIK 0001789042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 F1 · price: The purchase price reported above is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.13 to $3.14, inclusive. The reporting person undertakes to provide to Aptose Biosciences Inc.., any security holder of Aptose Biosciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 01:48 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Options (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001104659-23-095016 · tm2324788-1_4seq1.xml · derivative · entry 2 Seizinger Bernd R. · CIK 0001789042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2033-08-23 F2 · derivative.exercise_date: The option vests in full on August 23, 2024, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| August 23, 2023 Filed Aug 25, 2023 01:48 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-095016 · tm2324788-1_4seq1.xml · nonDerivative · entry 1 Seizinger Bernd R. · CIK 0001789042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,825 F1 · shares: These shares represent restricted stock units which were granted on August 23, 2023, and which will vest and be settled in common stock on August 23, 2024, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 20:34 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchaseCommon Stock | 6,029 | $3.68 | $22,192.15 |
DisclosureSEC source: 0001104659-23-069421 · tm2318158-1_4seq1.xml · nonDerivative · entry 2 Seizinger Bernd R. · CIK 0001789042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,325 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.65 to $3.70, inclusive. The reporting person undertakes to provide to Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth. F3 · balance_after: Reflects a one-for-20 reverse split, effective as of 5:00 p.m. Eastern Time on February 10, 2023. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 20:34 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchaseCommon Stock | 4,068 | $3.63 | $14,764.40 |
DisclosureSEC source: 0001104659-23-069421 · tm2318158-1_4seq1.xml · nonDerivative · entry 1 Seizinger Bernd R. · CIK 0001789042 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,296 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.4984 to $3.75, inclusive. The reporting person undertakes to provide to Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth. Read SEC document |
| January 19, 2023 Filed Jan 24, 2023 01:03 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001567619-23-001169 · doc1.xml · derivative · entry 1 Seizinger Bernd R. · CIK 0001789042 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Shares · 100,000 shares Expires 2033-01-19 F1 · derivative.exercise_date: Fifty percent (50%) of the options vest on January 19, 2024, twenty-five percent (25%) vest on January 19, 2025, and twenty-five percent (25%) vest on January 19, 2026. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 21:32 UTC | Aptose Biosciences Inc. APTO · Entity 33387 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0001567619-22-017563 · doc1.xml · derivative · entry 1 Seizinger Bernd R. · CIK 0001789042 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2032-09-14 F1 · shares: Fifty percent (50%) of the options vest on September 14, 2023, twenty-five percent (25%) on September 14, 2024, and twenty-five percent (25%) on September 14, 2025. F1 · derivative.exercise_date: Fifty percent (50%) of the options vest on September 14, 2023, twenty-five percent (25%) on September 14, 2024, and twenty-five percent (25%) on September 14, 2025. Read SEC document |
| July 28, 2022 Filed Aug 1, 2022 21:06 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Option (right to Buy) · Derivative | 29,575 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0001104659-22-084775 · tm2222147-10_4seq1.xml · derivative · entry 2 Seizinger Bernd R. · CIK 0001789042 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,575 Underlying: Common Stock · 29,575 shares Expires 2032-07-28 F2 · derivative.exercise_date: The option vests in full on July 28, 2023, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| July 28, 2022 Filed Aug 1, 2022 21:06 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 5,995 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-084775 · tm2222147-10_4seq1.xml · nonDerivative · entry 1 Seizinger Bernd R. · CIK 0001789042 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,575 F1 · shares: These shares represent restricted stock units which were granted on July 28, 2022, and which will vest and be settled in common stock on July 28, 2023, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| May 18, 2022 Filed May 19, 2022 20:31 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | PurchaseCommon Stock | 50,000 | $0.71 | $35,500.00 |
DisclosureSEC source: 0001104659-22-062920 · tm2216022d2_4seq1.xml · nonDerivative · entry 1 Seizinger Bernd R. · CIK 0001789042 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,580 Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 23:00 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Option (Right to Buy) · Derivative | 22,750 | $0.00 Strike: $4.88 | $0.00 |
DisclosureSEC source: 0001567619-21-012872 · doc1.xml · derivative · entry 2 Seizinger Bernd R. · CIK 0001789042 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,750 Underlying: Common Stock · 22,750 shares Expires 2031-06-30 F2 · derivative.exercise_date: The option vests in full on June 30, 2022, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 23:00 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantCommon Stock | 4,610 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-012872 · doc1.xml · nonDerivative · entry 1 Seizinger Bernd R. · CIK 0001789042 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,580 F1 · shares: These shares represent restricted stock units which were granted on June 30, 2021, and which will vest and be settled in common stock on June 30, 2022, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 22:06 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | GrantStock Option (right to Buy) · Derivative | 5,600 | $0.00 Strike: $38.78 | $0.00 |
DisclosureSEC source: 0000905148-20-000751 · form4.xml · derivative · entry 1 Seizinger Bernd R. · CIK 0001789042 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,600 Underlying: Common Stock · 5,600 shares Expires 2030-06-30 F1 · derivative.exercise_date: The option vests in full on June 30, 2021 subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. Read SEC document |
| October 07, 2019 Filed Oct 7, 2019 23:33 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | Exercise / conversionStock Option (right to buy) · Derivative | 263,970 | $0.00 Strike: $0.07 | $0.00 |
DisclosureSEC source: 0001140361-19-018086 · form4.xml · derivative · entry 2 Seizinger Bernd R. · CIK 0001789042 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 263,970 shares Expires 2025-09-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These options vested in connection with the completion of the Issuer's initial public offering. Read SEC document |
| October 07, 2019 Filed Oct 7, 2019 23:33 UTC | Aprea Therapeutics, Inc. APRE · Entity 7948 | Exercise / conversionCommon Stock | 263,970 | $0.07 | $18,477.90 |
DisclosureSEC source: 0001140361-19-018086 · form4.xml · nonDerivative · entry 1 Seizinger Bernd R. · CIK 0001789042 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,970 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.